Johns Hopkins Emergency Department finds more appropriate antibiotic treatment and shorter STI visits Read more

WEBINAR REPLAY

Advancing STI Diagnosis in Urgent Care: Point-of-Care Testing Solutions

Overview

During the webinar, we discussed how rates of STI are at an all-time high in the U.S. and globally, and how traditional send-outs for STD testing can lead to over/under-treatment and patients lost to care.

In an urgent care setting, the Visby Medical Sexual Health Test is a rapid, point-of care PCR STI test that can help reduce presumptive treatment as well as patient callbacks associated with send out testing, and the mitigate challenges with send-outs, improve clinic workflow, and enhance the patient experience.

Learning Objectives

In this video, participants will:

  • Review the rising rates of Sexually Transmitted Diseases (STD) in the United States and globally
  • Review today’s STI testing methods
  • Discuss the challenges and implications of today’s testing methods
  • Examine the clinical, operational and economic benefits of STD Point-Of-Care tests for urgent care

Access Includes:

 

About the Presenter

Dr. Gary Schoolnik is Chief Medical Officer, Visby Medical. He is also Professor of Medicine (emeritus), Stanford Medical School, Attending Physician in Internal Medicine and Infectious Diseases at Stanford University Hospital and Associate Director of Stanford’s Institute for Immunology, Transplantation and Infection.

Dr. Schoolnik received his M.D. degree and infectious diseases subspecialty training at the University of Washington in Seattle, served as medical intern, resident and chief resident at Harvard’s Massachusetts General Hospital in Boston and he was a research associate and associate physician at the Rockefeller University in Manhattan. While on the Stanford Medical School faculty he served as Chief of the Division of Infectious Diseases and Geographic Medicine. National service included his appointment to the Advisory Council of the National Institutes of Allergy and Infectious Diseases of the NIH and his role as chair of the NIH Trans-Institute Committee on the Human Microbiome and co-chair of the NIH Blue Ribbon Committee on Bioterrorism. International consultative activities include the Board of Scientific Counselors of Fudan University in Shanghai. He was founding editor of the journal Molecular Microbiology and Associate Editor of the Journal of Clinical Investigation. His academic research focuses on the molecular, genetic and genomic aspects of infectious agents and on the development of new drugs, vaccines and diagnostics. Gary has 6 issued patents.

Full lists of publications: visit https://profiles.stanford.edu/gary-schoolnik